Florida's attorney general has filed suit against pharmacy benefit managers Express Scripts, a unit of Cigna (CI), and Prime Therapeutics, accusing the rival drug middlemen of engaging in illegal price-fixing that has gutted reimbursements to the state's pharmacies and threatened patient access to medications.

Pharmaceutical companies have sharply accelerated their embrace of artificial intelligence, striking a wave of partnerships and acquisitions since the start of 2025 as they seek to compress drug development timelines and reduce costs through automation and advanced molecular modelling.

A US federal court has ordered Guardant Health (GH) to pay more than $245.2mn to TwinStrand Biosciences and the University of Washington after finding the cancer diagnostics company had infringed patents covering DNA sequencing technology.

Argenx SE (ARGX) has staged one of Europe's most striking biotech rallies in recent memory. The company’s dramatic gains last month have propelled the Belgian biotech’s market capitalization to €55.4bn ($64.8bn), overtaking Moderna (MRNA), whose own market value has more than doubled over the same period following its own dramatic run.

The US Food and Drug Administration has approved Gilead Sciences' (GILD) once-daily oral combination pill for the treatment of adults whose HIV infection has already been reduced to undetectable levels, the California-based drugmaker said.

Kimberly-Clark (KMB) has filed for European Union regulatory approval of its proposed $40bn acquisition of Kenvue (KVUE), according to documents published on the European Commission's website, as the consumer goods company advances its most ambitious deal in years.

The Trump administration has unveiled a second wave of drug pricing agreements under its most favored nation, or MFN, policy framework, this time securing deals with nine mid-sized pharmaceutical companies including Alcon (ALC), Astellas Pharma (ALPMY), BeOne Medicines (ONC), BridgeBio (BBIO), CSL, Kyowa Kirin (4151), Sun Pharma (SUNPHARMA), Teva Pharmaceuticals (TEVA) and UCB (UCB).

Alnylam Pharmaceuticals (ALNY) has lowered its full-year 2026 sales guidance by approximately $200mn, blaming slower-than-expected growth in its transthyretin, or TTR, amyloidosis franchise after initial launch demand normalized — a disclosure that sent the company's shares tumbling more than 28 per cent.

Celon Pharma (CLNP) said its experimental semaglutide product Reduzek demonstrated comparable absorption to Novo Nordisk's (NVO) Ozempic and Wegovy in an early-stage bioequivalence study, sending shares in the Polish drugmaker up 14.7 per cent — on course for their best single-day gain since July 2024.

The US Food and Drug Administration has cleared a blood test developed by Roche (RHHBY) and Eli Lilly (LLY) to help identify signs of Alzheimer's disease in patients aged 55 and older experiencing cognitive decline, marking another step in the industry's push to make diagnosis simpler and more accessible.

Eli Lilly (LLY) has launched Foundayo, its oral weight-loss and diabetes treatment, in the United Kingdom, making Britain the first country in Europe where the pill is available following regulatory approval earlier this month.

European regulators have laid out in greater detail the concerns underpinning their decision to strip the rare disease drug Tavneos of its marketing authorization in the European Union, alleging serious breaches of clinical trial protocol that they say fundamentally undermine the evidence base supporting the complement inhibitor.

In the private dining room of a San Francisco steakhouse in January, Albert Bourla cut a confident figure. The Pfizer (PFE) chief executive joked with reporters as he fielded questions about his company and the broader pharmaceutical landscape, his mood seemingly untouched by the pressures bearing down on the drugmaker he has led since 2019.

Karyopharm Therapeutics (KPTI) is racing to secure financing or a lender waiver before a $15.8mn loan payment falls due on September 10, after a deepening second-quarter loss left the company with just $65.4mn in cash and a runway extending only into next month.

Nestlé is seeking to transform the rise of GLP-1 weight-loss drugs from an existential threat into a commercial opportunity, using artificial intelligence and nutritional science to develop products aimed at the growing cohort of consumers taking medicines such as Ozempic and Wegovy.

Glancy Prongay Wolke & Rotter LLP, a national shareholder rights law firm, is investigating potential securities law violations at Alnylam Pharmaceuticals (ALNY) after the Cambridge, Massachusetts-based RNA interference specialist slashed its revenue outlook, sending its shares tumbling nearly 30 per cent.

Sandoz (SDZ) has agreed to pay up to $77mn upfront to Shanghai Henlius Biotech (2696) for licensing rights to three biosimilar drugs, as the Swiss generics group moves to expand its pipeline ahead of what it describes as an unprecedented wave of biologic patent expiries over the coming decade.

The US Food and Drug Administration has granted accelerated approval to Bristol Myers Squibb's (BMY) oral combination treatment for patients with a rare form of blood cancer whose illness had relapsed or failed to respond to existing therapies.

Eli Lilly (LLY) has filed six lawsuits against US companies it accuses of illegally selling unauthorized versions of its experimental obesity drug retatrutide, escalating its crackdown on black-market sellers before the medicine has received regulatory approval.

AstraZeneca (AZN) has discontinued a late-stage lung cancer trial involving its experimental immunotherapy volrustomig, marking the latest in a series of clinical and regulatory setbacks that have raised questions about the depth of the UK drugmaker's pipeline.